Drug: Granix (tbo-filgrastim)

Manufacturer: Teva

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication: for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia in adult and pediatric patients 1
month and older

Disease: neutropenia associated with myelosuppressive anti-cancer therapy

Therapeutic Area: Hematology, Oncology

Enrollment Form Link: Financial Assistance

Phone Number: N/A

Fax Number: N/A

Product Website: granix.com